Phenotypes Associated with This Genotype

Genotype
MGI:5295465

• Allelic Composition: Ptpn11^tm1Ckq/Ptpn11⁺; Tg(Mx1-cre)1Cgn/0
• Genetic Background: involves: 129S6/SvEvTac * C57BL/6 * C57BL/6J * CBA

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

Increased spleen weight in Ptpn11^tm1Ckq/Ptpn11⁺ Tg(Mx1-cre)1Cgn/0 mice

mortality/aging

premature death ( J:177285 )

• by 56 weeks due to leukemia in pIpC-treated mice

hematopoietic system

increased lymphoblastic lymphoma incidence ( J:177285 )

• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice

enlarged spleen ( J:177285 )

• in pIpC-treated mice

increased spleen weight ( J:177285 )

• in pIpC-treated mice

arrested B cell differentiation ( J:177285 )

• around the pro-B stage in pIpC-treated mice

myeloid hyperplasia ( J:177285 )

• all pIpC-treated mice develop myeloproliferative disease (MPD)

• Mac-1+/Gr-1+ mature myeloid cells are increased

• 5 of 27 pIpC-treated mice exhibit accelerated MPD

extramedullary hematopoiesis ( J:177285 )

• hyperproliferation in the liver and spleen in pIpC-treated mice

anemia ( J:177285 )

• progressive in pIpC-treated mice

abnormal bone marrow cell morphology/development ( J:177285 )

• pIpC-treated mice exhibit decreased common myeloid progenitors, granulocyte macrophage progenitors, and megakaryocyte erythroid progenitors compared with wild-type mice

• however, common lymphoid progenitor numbers are normal

decreased common myeloid progenitor cell number ( J:177285 )

• in pIpC-treated mice

increased leukocyte cell number ( J:177285 )

• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice

increased neutrophil cell number ( J:177285 )

• in pIpC-treated mice

decreased hematopoietic stem cell number ( J:177285 )

• 3-fold in the bone marrow in pIpC-treated mice

increased hematopoietic stem cell number ( J:177285 )

• in the spleen of pIpC-treated mice

abnormal hematopoietic stem cell physiology ( J:177285 )

• hematopoietic stem cells are hyperactivated in pIpC-treated mice

• hematopoietic stem cell quiescent in pIpC-treated mice is decreased 2-fold while the S and G2/M phase were doubled compared to in wild-type mice

• apoptosis of hematopoietic stem cells in pIpC-treated mice is decreased compared to in wild-type mice

neoplasm

increased lymphoblastic lymphoma incidence ( J:177285 )

• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice

increased leukemia incidence ( J:177285 )

• after 12 to 32 weeks of chronic myeloproliferative disease in pIpC-treated mice

increased acute lymphoblastic leukemia incidence ( J:177285 )

• B and T cell lymphoblastic leukemia/lymphoma in pIpC-treated mice

increased acute promyelocytic leukemia incidence ( J:177285 )

• acute myeloid leukemia in 6 of 27 pIpC-treated mice

increased B cell derived lymphoma incidence ( J:177285 )

• B cell lymphoblastic leukemia/lymphoma in 2 of 27 pIpC-treated mice

cellular

aneuploidy ( J:177285 )

• in bone marrow cells and splenocytes from pIpC-treated mice

chromosomal instability ( J:177285 )

• in pIpC-treated mice due to centrosome amplification

liver/biliary system

enlarged liver ( J:177285 )

• in pIpC-treated mice

immune system

increased lymphoblastic lymphoma incidence ( J:177285 )

• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice

enlarged spleen ( J:177285 )

• in pIpC-treated mice

increased spleen weight ( J:177285 )

• in pIpC-treated mice

arrested B cell differentiation ( J:177285 )

• around the pro-B stage in pIpC-treated mice

myeloid hyperplasia ( J:177285 )

• all pIpC-treated mice develop myeloproliferative disease (MPD)

• Mac-1+/Gr-1+ mature myeloid cells are increased

• 5 of 27 pIpC-treated mice exhibit accelerated MPD

increased leukocyte cell number ( J:177285 )

• extremely high after 32 weeks with leukemia infiltration in nonhematopoietic organs of pIpC-treated mice

increased neutrophil cell number ( J:177285 )

• in pIpC-treated mice

endocrine/exocrine glands

increased lymphoblastic lymphoma incidence ( J:177285 )

• T cell lymphoblastic leukemia/lymphoma in 9 of 27 pIpC-treated mice

growth/size/body

enlarged liver ( J:177285 )

• in pIpC-treated mice

enlarged spleen ( J:177285 )

• in pIpC-treated mice

increased spleen weight ( J:177285 )

• in pIpC-treated mice